Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax is set to release its quarterly earnings on May 9, 2025, with analysts expecting earnings per share of $0.19 and projected revenue of $204.1 million. The company’s recent multi-billion-dollar ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD- Utah study ...

Shares of Novavax, Inc. (NVAX) traded 16% higher on Thursday morning after the company reported upbeat first-quarter (Q1) ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.